Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

NCTNCT06182891 (opens ClinicalTrials.gov in a new tab)Other idXYFY2021-KL236-02
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
300 participants (actual)
Sponsor
The Affiliated Hospital of Xuzhou Medical University · Other
Design
Randomized · Open label (no masking)
Countries
1 country

China

Start
30 Oct 2021
Primary completion
30 Jun 2023
Completion
30 Oct 2023
First posted
27 Dec 2023
Last update posted
27 Dec 2023
Conditions
Type 2 Diabetic Nephropathy

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2021202220232024
  1. N/A

    Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

    NCT06182891

    30 Oct 2021 to 30 Oct 2023

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.

Interventions

  • Dulaglutide InjectionDrug

Arms2

  • Experimental

    Dulaglutide

    Dulaglutide was injected subcutaneously at standard dose and frequency for consecutive 12 months.

  • Active comparator

    other hypoglycemic agents not including GLP-1 receptor agonists

    Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Evaluation of the urinary albumin-to-creatinine ratio

    Time frame · 3,6 and 12 months after dulaglutide injection treatment

    Registry description

    the changes in the urinary albumin-to-creatinine ratio

  2. Evaluation of the biomarkers of the epithelial-mesenchymal transition process

    Time frame · 3,6 and 12 months after dulaglutide injection treatment

    Registry description

    the changes in the biomarkers of the epithelial-mesenchymal transition process from the baseline at 3, 6 and 12 months. These biomarkers of the epithelial-mesenchymal transition process include E-cadherin and periostin.

Secondary outcomes(3)

  1. Evaluation of the estimated glomerular filtration rate

    Time frame · 3,6 and 12 months after dulaglutide injection treatment

    Registry description

    the changes in the estimated glomerular filtration rate

  2. Evaluation of the cystatin C

    Time frame · 3,6 and 12 months after dulaglutide injection treatment

    Registry description

    the changes in the cystatin C

  3. Evaluation of adverse event

    Time frame · 3,6 and 12 months after dulaglutide injection treatment

    Registry description

    Tolerability and safety outcomes included the incidence of hypoglycemia, gastrointestinal reaction and other adverse events, which were recorded in detail at follow-up (3,6 and 12 months after dulaglutide injection treatment).

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Meta-analysis (pooled) · 2025

15 results

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.

Natale et al. 2025The Cochrane database of systematic reviewscited by 8

PMID 39963952PMC11834151DOI 10.1002/14651858.cd015849.pub2PUB-39963952

Rights unknown15 results
Source linkSee results (15)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * All adults aged 18 and above * No minors involved in the study * Diabetic Nephropathy defined as a urinary albumin-to-creatinine ratio ≥30 mg/g at least twice in three measurements within a period of 3-6 months Exclusion Criteria: * Patients with other types of kidney disease * Urinary tract infection * Type 1 diabetes

PepBank is a research reference. Talk to a doctor before you use any peptide.